Clinical Trials, Medical Devices, Sectors, Technology

Reliable Cervical Cancer Screening

By Oncgnostics

Based on available study data, GynTect^® provides a clear indication of malignancy status in patients with abnormal Pap smear: In all previous studies, GynTect was able to detect all cancer cases of the cervix (Sensitivity = 100%).

GynTect is rarely positive in cytological normal patients (Specificity = 96.6%). Cancer occurs via the histopathology defined dysplasia CIN1, CIN2 and CIN3. GynTect detection rates for this dysplasia increase continuously. This indicates a prognostic value of the GynTect cancer marker.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.